Methylation of SDC2/TFPI2 and Its Diagnostic Value in Colorectal Tumorous Lesions

Zhang, Lianglu; Dong, Lanlan; Lu, Changming; Huang, Wenxian; Yang, Cuiping; Wang, Qian; Lei, Ruixue; Sun, Rui; Wan, Kangkang; Li, Tingting; Sun, Fan; Gan, Tian; Lin, Jie; Yin, Lei

doi:10.3389/fmolb.2021.706754

Cited by 24 publications

(19 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, the promoter hypermethylation events can downregulate gene expression, but it is not always the case. For example, the hypermethylated SDC2 has been successfully commercialized for the early detection of colorectal cancer [46-48], while an apparent contradiction is that its expression increased in colorectal cancer, and the upregulated expression promotes cancer development [49-51]. Relatively, the relationship between hypermethylation events in gene body and expression is more complex.…”

Section: Discussionmentioning

confidence: 99%

Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection

Xia

Zhao

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundNumerous studies have revealed aberrant DNA methylation in esophageal squamous cell carcinoma (ESCC). However, they often focused on the partial genome, which resulted in an inadequate understanding of the shaped methylation features and the lack of available methylation markers for this disease.MethodsThe current study investigated the methylation profiles between ESCC and paired normal samples using whole-genome bisulfite sequencing (WGBS) data and obtained a group of differentially methylated CpGs (DMC), differentially methylated regions (DMR), and differentially methylated genes (DMG). The DMGs were then verified in independent datasets and Sanger sequencing in our custom samples. Finally, we attempted to evaluate the performance of these genes as methylation markers for the classification of ESCC and multiple cancer types.ResultsWe obtained 438,558 DMCs, 15,462 DMRs, and 1,568 DMGs. The four significantly enriched gene families of DMGs were CD molecules, NKL subclass, HOXL subclass, and Zinc finger C2H2-type. The HOXL subclass homeobox genes were observed extensively hypermethylated in ESCC and nine other cancer types. The HOXL-score estimated by HOXC10 and HOXD1 methylation showed good ability in discriminating ESCC from normal samples, while the methylation of GSX1 displayed potential utility for pan-cancer detection.ConclusionsWe observed widespread hypomethylation events in ESCC, and the hypermethylated HOXL subclass homeobox genes presented promising applications for the early detection of multiple cancer types.

show abstract

Section: Discussionmentioning

confidence: 99%

Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection

Xia

Zhao

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The level of regional methylation can be used as a biomarker for the early diagnosis of colorectal cancer. With the advancement of technology, other specific gene methylation levels in plasma, such as RASSF2 , sFPR1 , SDC2 and other gene promoter methylation, have been confirmed for use as biomarkers for the early diagnosis of colorectal cancer[ 19 - 21 ]. In addition, the determination of Septin 9 methylation in plasma is considered a sensitive and specific biomarker for the early diagnosis of colorectal cancer; however, when it is used for screening in general risk populations of colorectal cancer, it can only be detected.…”

Section: Discussionmentioning

confidence: 99%

“…RASSF1A hypermethylation is a promising biomarker for the diagnosis of HCC in tissue and blood and is an emerging biomarker for HCC[ 24 - 26 ]. In addition, RASSF1A hypermethylation is an early and potential prognostic biomarker in CRC[ 21 , 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma

Li¹,

Li²,

Run³

et al. 2022

WJGO

View full text Add to dashboard Cite

BACKGROUND Studies have validated the potential of methylated cell-free DNA as a biomarker in various tumors, and methylated DNA in plasma may be a potential biomarker for cancer. AIM To evaluate the diagnostic value of RASSF1A methylation in plasma for colorectal cancer (CRC) and hepatocellular carcinoma (HCC). METHODS A total of 92 CRC patients, 67 colorectal polyp (CRP) patients, 63 HCC patients, and 66 liver cirrhosis (LC) patients were enrolled. The plasma DNA was subjected to DNA extraction, double-strand DNA concentration determination, bisulfite conversion, purification, single-strand DNA concentration determination, and digital polymerase chain reaction (PCR) detection. The methylation rate was calculated. The diagnostic value was evaluated by the area under the curve (AUC). RESULTS The age and sex in the CRC and CRP groups and the HCC and LC groups were also matched. The DNA methylation rate of RASSF1A in plasma in the CRC group was 2.87 ± 1.80, and that in the CRP group was 1.50 ± 0.64. DNA methylation of RASSF1A in plasma showed a significant difference between the CRC and CRP groups. The AUC of RASSF1A methylation for discriminating the CRC and CRP groups was 0.82 (0.76-0.88). The AUCs of T1, T2, T3 and T4 CRC and CRP were 0.83 (0.72-0.95), 0.87 (0.78-0.95), 0.86 (0.77-0.95), and 0.75 (0.64-0.85), respectively. The DNA methylation rate of RASSF1A in plasma in the HCC group was 4.45 ± 2.93, and that in the LC group was 2.46 ± 2.07. DNA methylation of RASSF1A in plasma for the HCC and LC groups showed a significant difference. The AUC of RASSF1A methylation for discriminating the HCC and LC groups was 0.70 (0.60-0.79). The AUCs of T1, T2, T3 and T4 HCC and LC were 0.80 (0.61, 1.00), 0.74 (0.59-0.88), 0.60 (0.42-0.79), and 0.68 (0.53-0.82), respectively. CONCLUSION RASSF1A methylation in plasma detected by digital PCR may be a potential biomarker for CRC and HCC.

show abstract

“…Aberrant methylation of the SDC2 gene has also been shown to be involved in the pathogenesis of CRC. Its detection is possible from a tissue, blood, or stool sample, and the marker has been shown largely in late-stage III/IV disease [99]. A serum blood test has been developed, which looks at the methylation of a combination of Sept9 and SDC2 for use in the early detection of CRC, which is still awaiting approval.…”

Section: Dna-based Molecular Markers and Testsmentioning

confidence: 99%

Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection

Kamel

Eltarhoni

Nisar

et al. 2022

Cancers

View full text Add to dashboard Cite

Globally, colorectal cancer (CRC) is the third most common cancer, with 1.4 million new cases and over 700,000 deaths per annum. Despite being one of the most common cancers, few molecular approaches to detect CRC exist. Carcinoembryonic antigen (CEA) is a known serum biomarker that is used in CRC for monitoring disease recurrence or response to treatment. However, it can also be raised in multiple benign conditions, thus having no value in early detection or screening for CRC. Molecular biomarkers play an ever-increasing role in the diagnosis, prognosis, and outcome prediction of disease, however, only a limited number of biomarkers are available and none are suitable for early detection and screening of CRC. A PCR-based Epi proColon® blood plasma test for the detection of methylated SEPT9 has been approved by the USFDA for CRC screening in the USA, alongside a stool test for methylated DNA from CRC cells. However, these are reserved for patients who decline traditional screening methods. There remains an urgent need for the development of non-invasive molecular biomarkers that are highly specific and sensitive to CRC and that can be used routinely for early detection and screening. A molecular approach to the discovery of CRC biomarkers focuses on the analysis of the transcriptome of cancer cells to identify differentially expressed genes and proteins. A systematic search of the literature yielded over 100 differentially expressed CRC molecular markers, of which the vast majority are overexpressed in CRC. In terms of function, they largely belong to biological pathways involved in cell division, regulation of gene expression, or cell proliferation, to name a few. This review evaluates the current methods used for CRC screening, current availability of biomarkers, and new advances within the field of biomarker detection for screening and early diagnosis of CRC.

show abstract

Methylation of SDC2/TFPI2 and Its Diagnostic Value in Colorectal Tumorous Lesions

Cited by 24 publications

References 42 publications

Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection

Genome-wide methylation profiling identify hypermethylated HOXL subclass genes as potential markers for esophageal squamous cell carcinoma detection

RASSF1A methylation as a biomarker for detection of colorectal cancer and hepatocellular carcinoma

Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection

Contact Info

Product

Resources

About